Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy

Phenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data. We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels i...

Full description

Bibliographic Details
Main Authors: Saurabh K. Garg, Matthew J. Ott, A. G. M. Mostofa, Zhihua Chen, Y. Ann Chen, Jodi Kroeger, Biwei Cao, Adam W. Mailloux, Alisha Agrawal, Braydon J. Schaible, Amod Sarnaik, Jeffrey S. Weber, Anders E. Berglund, James J. Mulé, Joseph Markowitz
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00164/full
id doaj-27868eabfece4beba9ed09c42344dbf3
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Saurabh K. Garg
Matthew J. Ott
A. G. M. Mostofa
Zhihua Chen
Y. Ann Chen
Jodi Kroeger
Biwei Cao
Adam W. Mailloux
Alisha Agrawal
Braydon J. Schaible
Amod Sarnaik
Amod Sarnaik
Jeffrey S. Weber
Anders E. Berglund
James J. Mulé
James J. Mulé
Joseph Markowitz
Joseph Markowitz
Joseph Markowitz
spellingShingle Saurabh K. Garg
Matthew J. Ott
A. G. M. Mostofa
Zhihua Chen
Y. Ann Chen
Jodi Kroeger
Biwei Cao
Adam W. Mailloux
Alisha Agrawal
Braydon J. Schaible
Amod Sarnaik
Amod Sarnaik
Jeffrey S. Weber
Anders E. Berglund
James J. Mulé
James J. Mulé
Joseph Markowitz
Joseph Markowitz
Joseph Markowitz
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
Frontiers in Immunology
melanoma
nitric oxide
immune response
ipilimumab
flow cytometry
author_facet Saurabh K. Garg
Matthew J. Ott
A. G. M. Mostofa
Zhihua Chen
Y. Ann Chen
Jodi Kroeger
Biwei Cao
Adam W. Mailloux
Alisha Agrawal
Braydon J. Schaible
Amod Sarnaik
Amod Sarnaik
Jeffrey S. Weber
Anders E. Berglund
James J. Mulé
James J. Mulé
Joseph Markowitz
Joseph Markowitz
Joseph Markowitz
author_sort Saurabh K. Garg
title Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
title_short Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
title_full Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
title_fullStr Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
title_full_unstemmed Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
title_sort multi-dimensional flow cytometry analyses reveal a dichotomous role for nitric oxide in melanoma patients receiving immunotherapy
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2020-02-01
description Phenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data. We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels in peripheral blood immune cells before and after adjuvant ipilimumab co-administration with a peptide vaccine in melanoma patients. We analyzed inhibitory and stimulatory markers for immune cell phenotypes that were felt to be important in the NO analysis. The pipeline allows visualization of immune cell phenotypes without knowledge of clustering techniques and to categorize cells by association with relapse-free survival (RFS). Using this analysis, we uncovered the potential for a dichotomous role of NO as a pro- and anti-melanoma factor. NO was found in subsets of immune-suppressor cells associated with shorter-term (≤ 1 year) RFS, whereas NO was also present in immune-stimulatory effector cells obtained from patients with significant longer-term (> 1 year) RFS. These studies provide insights into the cell-specific immunomodulatory role of NO. The methods presented herein can be applied to monitor the pro- and anti-tumor effects of a variety of immune-based therapeutics in cancer patients.Clinical Trial Registration Number: NCT00084656 (https://clinicaltrials.gov/ct2/show/NCT00084656).
topic melanoma
nitric oxide
immune response
ipilimumab
flow cytometry
url https://www.frontiersin.org/article/10.3389/fimmu.2020.00164/full
work_keys_str_mv AT saurabhkgarg multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT matthewjott multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT agmmostofa multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT zhihuachen multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT yannchen multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT jodikroeger multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT biweicao multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT adamwmailloux multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT alishaagrawal multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT braydonjschaible multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT amodsarnaik multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT amodsarnaik multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT jeffreysweber multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT anderseberglund multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT jamesjmule multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT jamesjmule multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT josephmarkowitz multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT josephmarkowitz multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
AT josephmarkowitz multidimensionalflowcytometryanalysesrevealadichotomousrolefornitricoxideinmelanomapatientsreceivingimmunotherapy
_version_ 1725103007283019776
spelling doaj-27868eabfece4beba9ed09c42344dbf32020-11-25T01:27:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-02-011110.3389/fimmu.2020.00164496216Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving ImmunotherapySaurabh K. Garg0Matthew J. Ott1A. G. M. Mostofa2Zhihua Chen3Y. Ann Chen4Jodi Kroeger5Biwei Cao6Adam W. Mailloux7Alisha Agrawal8Braydon J. Schaible9Amod Sarnaik10Amod Sarnaik11Jeffrey S. Weber12Anders E. Berglund13James J. Mulé14James J. Mulé15Joseph Markowitz16Joseph Markowitz17Joseph Markowitz18Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesCancer Informatics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesFlow Cytometry Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Oncologic Sciences, USF Health Morsani College of Medicine, University of South Florida, Tampa, FL, United StatesDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Oncologic Sciences, USF Health Morsani College of Medicine, University of South Florida, Tampa, FL, United StatesDepartment of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, United StatesDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United StatesDepartment of Oncologic Sciences, USF Health Morsani College of Medicine, University of South Florida, Tampa, FL, United StatesPhenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data. We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels in peripheral blood immune cells before and after adjuvant ipilimumab co-administration with a peptide vaccine in melanoma patients. We analyzed inhibitory and stimulatory markers for immune cell phenotypes that were felt to be important in the NO analysis. The pipeline allows visualization of immune cell phenotypes without knowledge of clustering techniques and to categorize cells by association with relapse-free survival (RFS). Using this analysis, we uncovered the potential for a dichotomous role of NO as a pro- and anti-melanoma factor. NO was found in subsets of immune-suppressor cells associated with shorter-term (≤ 1 year) RFS, whereas NO was also present in immune-stimulatory effector cells obtained from patients with significant longer-term (> 1 year) RFS. These studies provide insights into the cell-specific immunomodulatory role of NO. The methods presented herein can be applied to monitor the pro- and anti-tumor effects of a variety of immune-based therapeutics in cancer patients.Clinical Trial Registration Number: NCT00084656 (https://clinicaltrials.gov/ct2/show/NCT00084656).https://www.frontiersin.org/article/10.3389/fimmu.2020.00164/fullmelanomanitric oxideimmune responseipilimumabflow cytometry